PLEGRIDY (peginterferon beta-1a) is an interferon beta-1a to which a single, linear 20,000 dalton (Da) methoxy poly(ethyleneglycol)-O-2-methylpropionaldehyde molecule is covalently attached to the alpha amino group of the N-terminal amino acid residue.
PLEGRIDY (peginterferon beta-1a) is indicated for the treatment of patients with relapsing forms of multiple sclerosis.
Clinical Trials Related to Plegridy (Peginterferon Beta-1A)
Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterferon Beta-1a) and Rebif� (Interferon Beta-1a) in Healthy Volunteers [Completed]
The primary outcome of the study is to evaluate the cumulative area under the concentration
time curve (AUC) over 2 weeks, as measured by AUC from time 0 to 336 hours post dose
(AUC0-336h), for serum concentrations of BIIB017 and Rebif.
The secondary outcomes are to evaluate the maximum observed serum concentrations (Cmax) of
BIIB017 and Rebif and to evaluate the safety and tolerability of BIIB017 and Rebif over 2
weeks in healthy volunteers.
Biogen Multiple Sclerosis Pregnancy Exposure Registry [Recruiting]
The primary objective of the study is to prospectively evaluate pregnancy outcomes in women
with multiple sclerosis who were exposed to a Registry-specified Biogen Multiple Sclerosis
product during the eligibility window for that product. The Registry-specified Biogen MS
products being studied are dimtheyl fumarate and Pegylated human interferon beta-1a.
Long-Term Safety and Efficacy Study of Peginterferon Beta-1a [Active, not recruiting]
The primary objective of this study is to evaluate the long-term safety and tolerability of
peginterferon beta-1a (BIIB017) in participants originally treated in Study 105MS301
(NCT00906399) who continue peginterferon beta-1a treatment. The secondary objective of this
study is to describe long-term multiple sclerosis (MS) outcomes in participants originally
treated in Study 105MS301 (NCT00906399) who continue peginterferon beta-1a treatment.
Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis [Completed]
The primary objective of this study is to determine the efficacy of peginterferon beta-1a in
reducing the annualized relapse rate (ARR) in participants with relapsing multiple sclerosis
(RMS) at 1 year. The secondary objectives of this study are to determine whether
peginterferon beta-1a, at 1 year when compared with placebo, is effective in reducing the
total number of new or newly enlarging T2 hyperintense lesions on brain magnetic resonance
imaging (MRI) scans, reducing the proportion of participants who relapse, and slowing the
progression of disability.
Page last updated: 2014-08-19